<DOC>
	<DOCNO>NCT00101153</DOCNO>
	<brief_summary>RATIONALE : Tipifarnib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cytarabine daunorubicin , work different way stop growth cancer cell , either kill cell stop divide . Giving tipifarnib together cytarabine daunorubicin may kill cancer cell . PURPOSE : This phase I trial study side effect best dose tipifarnib give cytarabine daunorubicin treat old patient acute myeloid leukemia .</brief_summary>
	<brief_title>Tipifarnib , Cytarabine , Daunorubicin Treating Older Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose tipifarnib administer cytarabine daunorubicin old patient previously untreated acute myeloid leukemia . - Determine toxicity regimen patient . - Determine pharmacokinetics regimen patient . OUTLINE : This multicenter , dose-escalation study tipifarnib . Induction therapy ( 1 course ) : Patients receive cytarabine IV continuously day 1-7 , daunorubicin IV day 6-8 , oral tipifarnib twice daily day 6-15 absence unacceptable toxicity . Patients achieve complete remission proceed consolidation therapy . Consolidation therapy ( 1 course ) : After hematologic recovery , patient begin consolidation therapy 35-60 day start induction therapy . Patients receive cytarabine , daunorubicin , tipifarnib induction therapy . Cohorts 3-6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A total 10 patient treat recommended phase II dose . Patients follow every 3 month . PROJECTED ACCRUAL : A total 3-28 patient accrue study within 1.5-22 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) All subtypes , except acute promyelocytic leukemia , allow At least 20 % bone marrow peripheral blood blast OR biopsyconfirmed extramedullary disease No cerebrospinal fluid involvement PATIENT CHARACTERISTICS : Age 56 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy Not specify Hematopoietic See Disease Characteristics WBC &lt; 100,000/mm^3 ( treatment hydroxyurea allow ) Hepatic Bilirubin ≤ 1.25 time upper limit normal ( ULN ) AST ALT ≤ 2.0 time ULN Renal Creatinine &lt; 1.7 mg/dL OR Creatinine clearance ≥ 60 mL/min Cardiovascular LVEF ≥ 50 % No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Immunologic HIV negative No history allergic reaction attribute compound similar chemical biologic composition tipifarnib imidazole drug ( e.g. , ketoconazole , clotrimazole , miconazole ) No ongoing active infection Other Not pregnant Fertile patient must use effective contraception Able swallow oral medication No uncontrolled illness No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy AML except hydroxyurea cytoreduction More 4 week since prior chemotherapy except hydroxyurea ( 6 week nitrosoureas mitomycin ) recover At least 24 hour since prior hydroxyurea Endocrine therapy No concurrent dexamethasone Radiotherapy More 4 week since prior radiotherapy recover No prior radiotherapy &gt; 3,000 cGy marrowproducing area Surgery Not specify Other No concurrent investigational agent No concurrent antileukemic agent No concurrent treatment follow : Ketoconazole Itraconazole Voriconazole Clarithromycin Erythromycin Phenytoin Carbamazepine Barbiturates Cyclosporine Pimozide Warfarin Grapefruit juice Simvastatin Lovastatin Atorvastatin No concurrent magnesium aluminumcontaining antacid within 2 hour tipifarnib administration</criteria>
	<gender>All</gender>
	<minimum_age>56 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
</DOC>